The U.S. Olympic team will be competing in Tokyo for first-place medals across many athletic events, each nation’s most physically-fit citizens going for gold. [embedded content] When it comes to the U.S. ranking on the world roster of population health outcomes, American ranks low on many key metrics, especially given that the U.S. does rank… Read More: Eli Lilly Bets on U.S. Well-Being at the Olympics »
AstraZeneca put the rest of the SGLT2 inhibitor class on notice when its Farxiga scored an FDA heart failure nod in patients with or without diabetes. One of its competitors, Eli Lilly and Boehringer Ingelheim’s Jardiance, is fast on Farxiga’s heels, though, and it’s ready to bring its pivotal trial win in front of physicians. Jardiance, added… Read More: ESC: Eli Lilly, Boehringer’s Jardiance cuts CV events by 25%… »
Last October, England’s drug-cost watchdogs dealt Eli Lilly a blow when they decreed that the company’s CDK 4/6 inhibitor to treat breast cancer, Verzenio, wasn’t cost-effective. So Lilly dished up a new price break—and now the National Institute for Health and Care Excellence (NICE) is on board. The problem, initially, was that Lilly couldn’t provide evidence that Verzenio… Read More: Lilly price break reverses NICE’s 'No' ruling on breast cancer… »